Enzomenib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia. It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins. Enzomenib targets tumors with KMT2A (MLL) rearrangements or NPM1 mutations. The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.
Enzomenib is an investigational new drug that is being evaluated for the treatment of acute leukemia. It is a small molecule inhibitor that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins. Enzomenib targets tumors with KMT2A (MLL) rearrangements or NPM1 mutations. The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Orphan Drug designations to Enzomenib.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1368211654 under CC BY-SA 4.0; modifications have been made.